Bayer: submits vericiguat for authorisation in China
(CercleFinance.com) - Bayer announced on Friday that it has submitted a registration to the Chinese health authorities for Vericiguat, its new treatment for patients suffering from chronic heart failure whose cases tend to worsen.
In a statement, the German chemical and pharmaceutical group points out that about 50% of heart failure patients are readmitted to hospital within 30 days of their heart failure episode, with each hospitalisation doubling the risk of death.
Bayer estimates that about 13.7 million people live with heart failure issues in China.
Vericiguat - developed in collaboration with the US Merck - is also the subject of applications for marketing authorisation from European and American authorities.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In a statement, the German chemical and pharmaceutical group points out that about 50% of heart failure patients are readmitted to hospital within 30 days of their heart failure episode, with each hospitalisation doubling the risk of death.
Bayer estimates that about 13.7 million people live with heart failure issues in China.
Vericiguat - developed in collaboration with the US Merck - is also the subject of applications for marketing authorisation from European and American authorities.
Copyright (c) 2020 CercleFinance.com. All rights reserved.